Navigation Links
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Date:8/14/2008

SEATTLE, Aug. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated its second of two new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The multicenter trial, called ProACT (PROstate Active Cellular Therapy), has begun enrolling 120 patients with metastatic, androgen independent prostate cancer.

All patients will receive active treatment but will be randomized into one of three cohorts which will receive PROVENGE manufactured with different concentrations of the immunizing antigen. Patients will receive three infusions of PROVENGE, each two weeks apart. The trial is being conducted by Dendreon to explore the effect of antigen concentration on CD54 upregulation, a measure of product potency, as well as the immune response. Overall survival data will also be collected. The enrollment criteria are essentially the same as the criteria for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) study, which completed enrollment in October 2007 and, upon receipt of positive data, will serve as the primary study for amending Dendreon's Biologics License Application (BLA) for PROVENGE.

"We are grateful for the continued support from patients, physicians and patient advocates and are pleased to be able to provide them with access to PROVENGE while we await results from the IMPACT trial," stated Mitchell H. Gold, president and chief executive officer of Dendreon.

ProACT is the second of two studies the Company is initiating. Dendreon recently announced it had begun enrolling patients in a 40-subject, single-center trial called Neo
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
(Date:8/27/2014)... Aug. 27, 2014 Research and ... "Global Lactic Acid  (Biodegradable Polymer, Food & Beverage, ... Forecasts to 2019" report to their offering. ... acid with an asymmetrical carbon atom. The main ... polymer, food and beverage, personal care product, and ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... QIAGEN (Nasdaq: QGEN , Frankfurt: QIA), which ... States offices in five locations, brought on board its ... as a symbol of the biotech company,s continued strong ... both in the U.S. and abroad. QIAGEN is the ...
... Phase 3 Combination Rule Trial for NDA Submission , ... BEDMINSTER, N.J., Dec. 15 QRxPharma Limited (ASX: QRX ... on the development and commercialization of therapies for pain ... of a comparative study to evaluate the efficacy and ...
... Inc. (Amex: ANX ), a biopharmaceutical company ... primarily for the treatment of cancer, today announced that ... the sale or disposition of one or more of ... other transactions that maximize the value of Company,s assets. ...
Cached Biology Technology:QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 2QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 3QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 4QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 3ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4
(Date:8/27/2014)... A growing number of consumers are willing to pay ... "organic", but whether they,re getting what the label claims ... tomatoes are devising a new way to make sure ... appears in ACS, Journal of Agricultural and Food ... Researchers from the Bavarian Health and Food Safety Authority ...
(Date:8/27/2014)... lost or abandoned each year in U.S. waters and ... to catch fish, crabs, and other species such as ... and the watermen who depend on the resources--losses that ... study. , The report, published in the Marine ... to examine the derelict fish trap problem, and so-called ...
(Date:8/27/2014)... main factors thought to be associated with outcomes ... the age of the patient, mechanism of injury, ... repair method, operation technique, and repair materials. However, ... of peripheral nerve injuries, there is no agreement ... and the dose-effect relationship of the predictors has ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... Researchers using an extremely fast and accurate imaging technique have ... shuttle material within living cells. The motors cooperate in a ... tug of war many scientists had imagined. , "We ... do not compete for control, even though they want to ...
... Yale, in collaboration with NIH researchers, have identified a ... system for detection of parasitic infections, leading the way ... , Published in the April 28 issue of Science ... parasites interface with the immune system--a problem of great ...
... from the first clinical trial of a therapeutic cancer ... (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported ... shows that the CpG 7909 DNA sequence is safe, ... destroy cancer cells. The Phase I study was conducted ...
Cached Biology News:Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows 2Yale researchers identify molecule for detecting parasitic infection in humans 2Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
Biology Products: